Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Galectin Therapeutics Inc GALT

Healthcare Biotechnology
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GALT)

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis

GlobeNewswire April 9, 2024

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

GlobeNewswire March 29, 2024

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

GlobeNewswire March 12, 2024

UPDATE - Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

GlobeNewswire November 13, 2023

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

GlobeNewswire November 13, 2023

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting(TM) 2023, Hosted by the AASLD

GlobeNewswire November 3, 2023

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

GlobeNewswire October 23, 2023

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

GlobeNewswire October 12, 2023

Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis

GlobeNewswire October 3, 2023
View More News ››

Opinion & Analysis (NDAQ:GALT)

Therapeutics Developer Secures Patents, Continues Phase 3 Trial Planning

Streetwise Reports December 27, 2018

'The market gets it wrong, again'; analyst raises target price on biotech

Streetwise Reports December 15, 2017

The Calandra Report: More biotech, Bitterroot, CTIX, BCRX, CUR and more

Thom Calandra January 14, 2014
View More Opinion ››

Bullboard Posts (NDAQ:GALT)

Galectin Therapeutics And 2 Other Penny Stocks Insiders Are

NEWS: $GALT Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying | BenzingaThe Dow Jones index closed higher by over 250...
whytestocks - 12 days ago

GALT Issues

The bull case on GALT is simply stated in this manner: 1.) The FDA has allowed them to go to Phase three on the strength of a portion of...
SPCEO1 - June 25, 2018

Links to articles related to GALT

http://psinvestor.com/galectin-therapeutics-from-an-investor-perspective/ http://emerginggrowth.com/cancers-last-stand-gr-md-02-nearly...
SPCEO1 - June 25, 2018

GALT Trading Signals

Today's rise by 8% was based on the liver therapy provided to patients, which came out with positive numbers.  However, other...
BluSignals - June 14, 2018

RE:RE:Galectin Therapeutics (GALT) Comments on GR-MD-02

IGNORE THIS SPAMMER-DOUGLASTILLO
goldguy007 - July 30, 2014

Galectin Therapeutics (GALT) Comments on GR-MD-02

Galectin Therapeutics (Nasdaq: GALT) announced yesterday results of cohort 2 of its phase 1 clinical trial in patients with NASH with...
goldguy007 - July 30, 2014
View more Bullboard ››

Lahontan Gold Corp.

Lahontan Gold Corp.

Lahontan Gold Corp. is a Canada-based mineral exploration company. The Company is engaged in the identification, acquisition, ...
View More »